Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Changhai Hospital | OTHER |
| Southwest Hospital, China | OTHER |
| General Hospital of Beijing PLA Military Region | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and effect of ulinastatin in inhalation lung injury patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| blank control group | Sham Comparator |
| |
| ulinastatin group | Experimental | ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ulinastatin | Drug | Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days |
|
| Measure | Description | Time Frame |
|---|---|---|
| all cause mortality | until death or discharge from hospital, data reviewed every 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| length of mechanical ventilation | from admission to 90 days | |
| length of ICU stay | until death or discharge from hospital, data reviewed every 3 months | |
| length of hospital stays |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sheng zhiyong, MD | Contact | 86-13910008199 | ||
| Jia chiyu, MD | Contact | JCY304@yahoo.com.cn |
| Name | Affiliation | Role |
|---|---|---|
| sheng zhiyong, MD | First Hospitals affiliated to the China PLA General Hospital | Study Chair |
| Jia chiyu, MD | First Hospitals affiliated to the China PLA General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 304 hospital of PLA | Beijin | Beijin | 100000 | China |
Not provided
| ID | Term |
|---|---|
| C028665 | urinastatin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| blank group | Drug | standard treatment |
|
| until death or discharge from hospital, data reviewed every 3 months |
| blood inflammatory mediator | 0days,5days and 10days |
| Bronchoscopy morphological evaluation | 0days,5days and 10days |
| Xia zhaofan, MD | Changhai Hospital | Principal Investigator |
| Pang yizhi, MD | Southwest Hospital, China | Principal Investigator |
| Chen tunhu, MD | General Hospital of Jinan PLA Military Region | Principal Investigator |
| Zhu jinmin, MD | General Hospital of Beijing PLA Military Region | Principal Investigator |
| Liu yi, MD | General Hospital of Lanzhou PLA Military Region | Principal Investigator |
| Cui xiaolin, MD | Liaonin People's Armed Police Corps Hospital | Principal Investigator |
| Sheng guanyu, MD | 187 Central Hospital of the Chinese PLA | Principal Investigator |
| Lu qinjun, MD | 251 Central Hospital of the Chinese PLA | Principal Investigator |
| Shi shengfu, MD | 322 Central Hospital of the Chinese PLA | Principal Investigator |